Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $13.00 target price on the stock.

IMRX has been the subject of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Immuneering in a report on Tuesday. Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.80.

Immuneering Trading Down 15.3 %

Shares of NASDAQ IMRX opened at $2.00 on Wednesday. The company has a 50-day moving average of $2.04 and a 200 day moving average of $1.77. Immuneering has a 12-month low of $1.00 and a 12-month high of $7.68. The stock has a market cap of $62.10 million, a PE ratio of -1.02 and a beta of -0.34.

Institutional Investors Weigh In On Immuneering

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vontobel Holding Ltd. purchased a new position in shares of Immuneering during the third quarter worth $25,000. Corsair Capital Management L.P. acquired a new position in Immuneering during the 3rd quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Immuneering during the 2nd quarter valued at about $44,000. XTX Topco Ltd grew its position in Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after acquiring an additional 9,274 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Immuneering in the 2nd quarter valued at about $67,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.